AAAAAA
Results:
1-12
|
Results: 12
Authors:
Kvinnsland, S
Anker, G
Dirix, LY
Bonneterre, J
Prove, AM
Wilking, N
Lobelle, JP
Mariani, O
di Salle, E
Polli, A
Massimini, G
Citation: S. Kvinnsland et al., High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment, EUR J CANC, 36(8), 2000, pp. 976-982
Authors:
Linderholm, B
Grankvist, K
Wilking, N
Johansson, M
Tavelin, B
Henriksson, R
Citation: B. Linderholm et al., Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment, J CL ONCOL, 18(7), 2000, pp. 1423-1431
Authors:
Wallberg, B
Michelson, H
Nystedt, M
Bolund, C
Degner, LF
Wilking, N
Citation: B. Wallberg et al., Information needs and preferences for participation in treatment decisionsamong Swedish breast cancer patients, ACTA ONCOL, 39(4), 2000, pp. 467-476
Authors:
Fokstuen, T
Wilking, N
Rutqvist, LE
Wolke, J
Liedberg, A
Signomklao, T
Fernberg, JO
Citation: T. Fokstuen et al., Radiation therapy in the management of brain metastases from breast cancer, BREAST CANC, 62(3), 2000, pp. 211-216
Authors:
Bergh, J
Wiklund, T
Erikstein, B
Lidbrink, E
Lindman, H
Malmstrom, P
Kellokumpu-Lehtinen, P
Bengtsson, NO
Soderlund, G
Anker, G
Wist, E
Ottosson, S
Salminen, E
Ljungman, P
Holte, H
Nilsson, J
Blomqvist, C
Wilking, N
Citation: J. Bergh et al., Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial, LANCET, 356(9239), 2000, pp. 1384-1391
Authors:
Ragnarson-Tennvall, G
Wilking, N
Citation: G. Ragnarson-tennvall et N. Wilking, Treatment of locally advanced pancreatic carcinoma in Sweden - A health economic comparison of palliative treatment with best supportive care versus palliative treatment with gemcitabine in combination with best supportive care, PHARMACOECO, 15(4), 1999, pp. 377-384
Authors:
Isaksson, E
Sahlin, L
Soderqvist, G
von Schoultz, E
Masironi, B
Wickman, M
Wilking, N
von Schoultz, B
Skoog, L
Citation: E. Isaksson et al., Expression of sex steroid receptors and IGF-1 mRNA in breast tissue - effects of hormonal treatment, J STEROID B, 70(4-6), 1999, pp. 257-262
Authors:
Nabholtz, JM
Senn, HJ
Bezwoda, WR
Melnychuk, D
Deschenes, L
Douma, J
Vandenberg, TA
Rapoport, B
Rosso, R
Trillet-Lenoir, V
Drbal, J
Molino, A
Nortier, JWR
Richel, DJ
Nagykalnai, T
Siedlecki, P
Wilking, N
Genot, JY
Hupperets, PSGJ
Pannuti, F
Skarlos, D
Tomiak, EM
Murawsky, M
Alakl, M
Riva, A
Aapro, M
Citation: Jm. Nabholtz et al., Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy, J CL ONCOL, 17(5), 1999, pp. 1413-1424
Authors:
Bostrom, A
Sjolin-Forsberg, G
Wilking, N
Bergh, J
Citation: A. Bostrom et al., Radiation recall - Another call with tamoxifen, ACTA ONCOL, 38(7), 1999, pp. 955-959
Authors:
Billgren, AM
Rutqvist, LE
Tani, E
Wilking, N
Fornander, T
Skoog, L
Citation: Am. Billgren et al., Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival, ACTA ONCOL, 38(5), 1999, pp. 597-601
Authors:
Lindman, H
Wiklund, T
Holte, H
Ljungman, P
Blomqvist, C
Kvalheim, G
Bengtsson, M
Hoglund, M
Wilking, N
Bergh, J
Citation: H. Lindman et al., FEC mobilized stem cells for high-dose therapy in breast cancer patients, ACTA ONCOL, 38(2), 1999, pp. 239-245
Authors:
Isaksson, E
Cline, JM
Skoog, L
Soderqvist, G
Wilking, N
von Schoultz, E
von Schoultz, B
Citation: E. Isaksson et al., p53 expression in breast and endometrium during estrogen and tamoxifen treatment of surgically postmenopausal cynomolgus macaques, BREAST CANC, 53(1), 1999, pp. 61-67
Risultati:
1-12
|